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Abstract: Dipeptide monoester prodrugs of ﬂoxuridine were synthesized, and their chemical stability
in buffers, resistance to glycosidic bond metabolism, afﬁnity for PEPT1, enzymatic activation and
permeability in cancer cells were determined and compared to those of mono amino acid monoester
ﬂoxuridine prodrugs. Prodrugs containing glycyl moieties were the least stable in pH 7.4 buffer (t1/2
< 100 min). The activation of all ﬂoxuridine prodrugs was 2- to 30-fold faster in cell homogenates
than their hydrolysis in buffer, suggesting enzymatic action. The enzymatic activation of dipeptide
monoester prodrugs containing aromatic promoieties in cell homogenates was 5- to 20-fold slower
than that of other dipeptide and most mono amino acid monoester prodrugs (t1/2 ∼ 40 to 100 min).
All prodrugs exhibited enhanced resistance to glycosidic bond metabolism by thymidine phospho-
rylase compared to parent ﬂoxuridine. In general, the 5′ -O-dipeptide monoester ﬂoxuridine prodrugs
exhibited higher afﬁnity for PEPT1 than the corresponding 5′ -O-mono amino acid ester prodrugs.
The permeability of dipeptide monoester prodrugs across Caco-2 and Capan-2 monolayers was 2-
to 4-fold higher than the corresponding mono amino acid ester prodrug. Cell proliferation assays in
AsPC-1 and Capan-2 pancreatic ductal cell lines indicated that the dipeptide monoester prodrugs
were equally as potent as mono amino acid prodrugs. The transport and enzymatic proﬁles of 5′ -
L-phenylalanyl-L-tyrosyl-ﬂoxuridine, 5′ -L-phenylalanyl-L-glycyl-ﬂoxuridine, and 5′ -L-isoleucyl-L-glycyl-
ﬂoxuridine suggest their potential for increased oral uptake, delayed enzymatic bioconversion and
enhanced resistance to metabolism to 5-ﬂuorouracil, as well as enhanced uptake and cytotoxic
activity in cancer cells, attributes that would facilitate prolonged systemic circulation for enhanced
therapeutic action.
Keywords: Dipeptide monoester ﬂoxuridine prodrugs; PEPT1; Caco-2 and Capan-2 perme-
ability; metabolism; thymidine phosphorylase
Introduction
The anticancer agent 5-ﬂuoro-2′ -deoxyuridine (ﬂoxu-
ridine) has been shown to be clinically effective in the
treatment of colon carcinoma and colorectal cancer that
has metastasized to the liver. However, the adverse effects
associated with chemotherapeutics are still unresolved, and
many efforts have been made to minimize side-effects and
maximize therapeutic efﬁcacy. Prodrug strategies have
been increasingly utilized over the past two decades in
order to overcome undesirable physicochemical properties
of drugs, to improve oral bioavailability and to minimize
toxic side-effects. A majority of the efforts have focused
on antiviral and anticancer drugs and reﬂect the need for
improved targeting, more selective action and further
development of orally available alternatives. Amino acid
ester prodrugs of poorly permeant anticancer and antiviral
drugs have been designed for targeted delivery Via speciﬁc
transporters in order to improve their oral bioavailability
and metabolic disposition.
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Published on Web 07/25/2008Amino acid ester prodrugs have been shown to be
substrates for PEPT1, PEPT2, and ATB
0,+ transporters, and
their improved oral bioavailability has been attributed to
enhanced transport Via carrier-mediated mechanisms.
4-9
Alkyl ester prodrugs and amino acid ester prodrugs of
ﬂoxuridine, for example, have been synthesized and tested
for potential improvement of oral drug delivery.
10-14 Amino
acid ester prodrugs of ﬂoxuridine and an antiviral agent,
acyclovir, have been shown to be substrates of the PEPT1
transporter.
14,15 PEPT1 is stereoselective and exhibits greater
afﬁnity for L-enantiomers of amino acids than D-enanti-
omers.
16 PEPT1 is predominantly expressed in the small
intestine, has broad substrate speciﬁcity and can transport
dipeptides, tripeptides, and  -lactam antibiotics.
6,17-23 The
valyl ester prodrug of acyclovir signiﬁcantly enhances oral
bioavailability of acyclovir, and several reports suggest that
oligopeptide transporters are responsible for absorption
enhancement.
15,24 Amino acid ester prodrugs may also
facilitate enhanced delivery to pancreatic ductal cancer cells
such as AsPC-1 and Capan-2, since these cells express
oligopeptide transporters at relatively high levels.
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transport is an essential step and cannot be ignored. It has
been shown that a speciﬁc enzyme, valacyclovirase, is
primarily responsible for the conversion of valacyclovir to
acyclovir. It has also been suggested that this enzyme might
be involved in the activation of other amino acid prodrugs.
26
Kim and colleagues reported that the substrate speciﬁcity of
valacyclovirase is largely determined by the amino acid acyl-
linked promoiety of the prodrug.
27
The metabolic conversion of ﬂoxuridine to 5-ﬂuorouracil
following systemic delivery has been shown to be detrimental
to therapeutic efﬁcacy of ﬂoxuridine.
28,29 The mechanism
of action of 5-ﬂuorouracil (5-FU) and ﬂoxuridine (FUdR) is
well understood.
30 5-FU toxicity is predominantly caused
by 5-FU incorporation into RNA. However, unlike 5-FU,
FUdR is speciﬁcally incorporated into DNA and not into
RNA, which leads to the minimization of adverse effects.
31-33
Several groups have reported that ﬂoxuridine is more potent
than 5-FU and that the inhibition of cell proliferation is 10-
to 100-fold higher than that of 5-FU.
28,29 However, ﬂoxu-
ridine is rapidly converted to 5-FU in many tissues, including
the liver, by the enzyme thymidine phosphorylase.
34 As a
consequence, higher doses of ﬂoxuridine are required for
maintenance of clinical efﬁcacy, leading to greater toxicity.
Therefore, protection of the glycosidic bond of ﬂoxuridine
is expected to maintain the high potency of the drug and
facilitate administration of low doses that can selectively kill
only proliferating cells by robust inhibition of DNA synthe-
sis. Improving the chemical stability of ﬂoxuridine to
thymidine phosphorylase may enhance its therapeutic ef-
ﬁcacy at low doses and obviate toxicity concerns.
Although amino acid monoester prodrugs of ﬂoxuridine
have been shown to provide enhanced PEPT1-mediated
transport as well as enzymatic activation in intestinal and
liver surrogate cell systems, dipeptide analogues may exhibit
even higher afﬁnity and transport Via the oligopeptide
transporter.
6,18,22,35 Therefore, dipeptide prodrugs may be
delivered more to a target site by carrier mediated transport-
ers, and extra amino acid attached prodrugs could be more
suitable for speciﬁc enzymatic activation at a target site than
mono amino acid ester prodrugs. Several studies on amino
acid modiﬁcations to increase speciﬁc transporter afﬁnity
have been conducted. However, direct comparisons of mono
amino acid and dipeptide prodrugs in terms of transporter
afﬁnity, prodrug stability and activation have not been
reported.
In this report, we describe the synthesis, characterization,
and stability of dipeptide monoester prodrugs of ﬂoxuridine.
Various dipeptides and peptidomimetics have been tested to
characterize the hPEPT1 transporter and improve its
afﬁnity,
6,17-19,22,35-37 and mono amino acid ester prodrugs
have been evaluated as hPEPT1 substrates.
3,13,14 Based on
those reports, six amino acids were chosen to be N-terminal
amino acids of the dipeptide. The smallest amino acid,
glycine, and bulky amino acids like phenylalanine and
tyrosine were paired with those six amino acids to form
dipeptides to test the hypothesis that molecular sizes may
structurally affect its ester bond stability. The six dipeptide
promoieties, L-phenylalanalyl-L-glycine, L-leucyl-L-glycine,
L-glycyl-L-leucine, L-isoleucyl-L-glycine, L-valyl-L-phenyla-
lanine, and L-phenylalanyl-L-tyrosine, were designed for
targeted delivery to an oligopeptide transporter and tested.
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for transporters than 3′ -ester prodrugs,
14 only 5′ -dipeptide
monoester ﬂoxuridine prodrugs were examined in this study.
Uptake inhibition and permeability studies were conducted
with Caco-2 cells as well as with AsPC-1 and Capan-2 cells.
The chemical stability at physiological pH and the enzymatic
activation of the prodrugs in Caco-2, AsPC-1, and Capan-2
cell homogenates were also evaluated to determine the effects
of the amino acid/dipeptide promoiety structure on enzyme-
mediated activation. The feasibility of selective antiprolif-
erative action of amino acid/dipeptide ﬂoxuridine prodrugs
was also explored using cancer cells that overexpress PEPT1.
Finally, the stability and transport characteristics of the
dipeptide monoester prodrugs of ﬂoxuridine were compared
with those of the corresponding amino acid monoester
prodrugs.
Materials and Methods
Materials. Floxuridine (FUdR) was obtained from
Lancaster (Windham, NH). The tert-butyloxycarbonyl
(Boc) protected amino acids Boc-L-isoleucine, Boc-L-
glycine, Boc-L-valine, Boc-L-phenylalanine, Boc-L-leucine,
Boc-L-glycyl-L-leucine, Boc-L-phenylalanalyl-L-glycine,
Boc-L-leucyl-L-glycine, Boc-L-isoleucyl-L-glycine, Boc-
L-valyl-L-phenylalanine, and Boc-L-phenylalanyl-L-ty-
rosine were obtained from Chem-Impex (Wood Dale, IL).
High-performance liquid chromatography (HPLC) grade
acetonitrile was obtained from Fisher Scientiﬁc (St. Louis,
MO). N,N-Dicyclohexylcarbodiimide (DCC), N,N-dim-
ethylaminopyridine
(DMAP), triﬂuoroacetic acid (TFA), and all other reagents
and solvents were purchased from Aldrich Chemical Co.
(Milwaukee, WI). Cell culture reagents were obtained from
Invitrogen (Carlsbad, CA), and cell culture supplies were
obtained from Corning (Corning, NY) and Falcon (Lincoln
Park, NJ). All chemicals were either analytical or HPLC
grade.
Floxuridine Prodrug Synthesis. The synthesis and char-
acterization of 5′ -mono amino acid ester prodrugs of ﬂoxu-
ridine have been reported previously.
11,13 Dipeptide prodrugs
of ﬂoxuridine were synthesized in a similar manner. Brieﬂy,
Boc-protected dipeptides Boc-L-glycyl-L-leucine, Boc-L-
phenylalanalyl-L-glycine, Boc-L-leucyl-L-glycine, Boc-L-iso-
leucyl-L-glycine, Boc-L-valyl-L-phenylalanine, and Boc-L-
phenylalanyl-L-tyrosine, (1.1 mmol), DCC (1.1 mmol), and
DMAP (0.1 mmol) were allowed to react with ﬂoxuridine
(1 mmol) in 7 mL of dry DMF for 24 h. The reaction
progress was monitored by TLC (ethyl acetate). The reaction
mixture was ﬁltered and DMF was removed under vacuum
at 40 °C. The residue was extracted with ethyl acetate (30
mL) and washed with water (2 × 20 mL), and saturated NaCl
(20 mL). The organic layer was dried over MgSO4 and
concentrated under vacuum. The reaction yielded a mixture
of 3′ -monoester, 5′ -monoester, and 3′ ,5′ -diester ﬂoxuridine
prodrugs. The three spots observed on TLC were separated
and puriﬁed using column chromatography (dichloromethane
(DCM)/methanol, 20:1). Fractions from each spot were
concentrated under vacuum separately. The Boc group was
cleaved by treating the residues with 5 mL TFA:DCM
(1:1). After 4 h, the solvent was removed and the residues
were reconstituted with water and lyophilized. The TFA salts
of amino acid prodrugs of ﬂoxuridine were obtained as white
ﬂuffy solids. The combined yield, consisting of 3′ -monoester,
5′ -monoester, and 3′ ,5′ -diesters, of each ﬂoxuridine prodrug
was ∼60%. The prodrugs were determined to be 90%-99%
pure by reverse-phase HPLC, and were easily separated from
their parent compounds by reverse-phase HPLC. The ob-
served molecular weights of all prodrugs, determined by
electrospray ionization mass spectra (ESI-MS) obtained on
a Micromass LCT ESI-MS, were found to be consistent with
those predicted by their structures. The structural identities
of the prodrugs were then conﬁrmed using proton nuclear
magnetic resonance spectra (
1H NMR), obtained on a 300
MHz Bruker DPX-300 NMR spectrometer.
5′ -L-Leucyl-L-glycyl-ﬂoxuridine: yield, 15%; percent pu-
rity, 93%;
1H NMR (DMSO-d6) δ, 0.84-0.92 (6H, m,
δ(CH3)2), 1.50-1.77 (3H, m,
 ,γCH2), 2.12-2.28 (2H, m,
C2′ ), 3.78-4.35 (7H, m,
RCH of Leu and
RCH2 of Gly, C3′ ,
C4′ ,C 5 ′ ), 6.16 (1H, t, C1′ , J ) 6.0 Hz), 7.94 (1H, d, CHF,
J ) 6.9 Hz); ESI-MS, 417.1 (M + H)
+.
5′ -L-Glycyl-L-leucyl-ﬂoxuridine: yield, 15%; percent pu-
rity, 96%;
1H NMR (DMSO-d6) δ, 0.85 (3H, d,
δCH3, J )
6.5 Hz), 0.90 (3H, d,
δCH3, J ) 6.5 Hz), 1.51-1.68 (3H,
m,
 ,γCH2), 2.12-2.26 (2H, m, C2′ ), 3.54-4.40 (7H, m,
RCH
of Leu and
RCH2 of Gly, C3′ ,C 4 ′ ,C 5 ′ ), 6.16 (1H, t, C1′ , J
) 6.0 Hz), 7.90 (1H, d, CHF, J ) 6.8 Hz); ESI-MS, 417.1
(M + H)
+.
5′ -L-Valyl-L-phenylalanyl-ﬂoxuridine: yield, 30%; percent
purity, 95%;
1H NMR (DMSO-d6) δ, 0.90 (3H, d,
γCH3, J
) 6.9 Hz), 0.95 (3H, d,
γCH3, J ) 6.9 Hz), 2.08-2.20 (3H,
m, C2′ ,
 CH of Val), 3.02 (2H, m,
 CH2 of Phe), 3.62-4.60
(6H, m,
RCH of Val and Phe, C3′ ,C 4 ′ ,C 5 ′ ), 6.14 (1H, t,
C1′ , J ) 6.1 Hz), 7.22-7.31 (5H, m, aromatic protons), 7.91
(1H, d, CHF, J ) 6.9 Hz); ESI-MS, 494.1 (M + H)
+.
5′ -L-Isoleucyl-L-glycyl-ﬂoxuridine: yield, 15%; percent
purity, 93%;
1H NMR (DMSO-d6) δ, 0.87 (3H, t,
δCH3,
J)7.3 Hz), 0.94 (3H, d,
γCH3, J ) 6.8 Hz), 1.17 (1H, m,
γCH2), 1.52 (1H, m,
γCH2), 1.81 (1H, m,
 CH), 2.11-2.28
(2H, m, C2′ ), 3.90-4.31 (7H, m,
RCH of Ile and
RCH2 of
Gly, C3′ ,C 4 ′ ,C 5 ′ ), 6.15 (1H, t, C1′ , J ) 6.5 Hz), 7.94 (1H,
d, CHF, J ) 6.9 Hz); ESI-MS, 416.9 (M + H)
+.
5′ -L-Phenylalanyl-L-glycyl-ﬂoxuridine: yield, 16%; percent
purity, 98%;
1H NMR (DMSO-d6) δ, 2.12-2.28 (2H, m,
C2′ ), 2.92-3.16 (2H, m,
 CH2 of Phe), 3.90-4.34 (7H, m,
RCH of Phe and
RCH2 of Gly, C3′ ,C 4 ′ ,C 5 ′ ), 6.15 (1H, t,
C1′ , J ) 6.5 Hz), 7.27-7.36 (5H, m, aromatic protons), 7.94
(1H, d, CHF, J ) 6.5 Hz); ESI-MS, 451.1 (M + H)
+.
5′ -L-Phenylalanyl-L-tyrosyl-ﬂoxuridine: yield, 3.2%; per-
cent purity, 99%;
1H NMR (DMSO-d6) δ, 2.10-2.32 (2H,
m, C2′ ), 2.72-2.92 (4H, m,
 CH2 of Phe and Tyr),
3.90-4.29 (6H, m,
RCH of Phe and Tyr, C3′ ,C 4 ′ ,C 5 ′ ), 6.15
(1H, m, C1′ ), 6.65-7.32 (9H, m, aromatic protons), 7.93
(1H, m, CHF); ESI-MS, 557.2 (M + H)
+.
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AsPC-1 cells (passages 63-65) from American type Culture
Collection (Rockville, MD) were routinely maintained in
RPMI-1640 containing 10% fetal bovine serum. Caco-2 cells
(passages 30-35) from American type Culture Collection
(Rockville, MD) were routinely maintained in DMEM
containing 10% fetal bovine serum, 1% nonessential amino
acids, 1 mmol/L sodium pyruvate, and 1% L-glutamine at
5% CO2 and 90% relative humidity at 37 °C. Cells were
grown in antibiotic-free media to avoid the possible transport
interference by antibiotics.
Hydrolysis Studies. (a) Enzymatic Stability. Conﬂuent
Caco-2, Capan-2, and AsPC-1 cells were rinsed twice with
saline. The cells were washed with 5 mL of pH 7.4 phosphate
buffer (10 mmol/L), lysed by ultrasonication (Micro ultra-
sonic cell disrupter model KT40, Kontes, Vineland, NJ), and
pelleted by centrifugation for 5 min at 1000g. Protein amount
was quantiﬁed with Bio-Rad (Hercules, CA) DC Protein
Assay using bovine serum albumin as a standard. The protein
amount was adjusted to 500 µg/mL, and the hydrolysis
reactions were carried out in 96-well plates (Corning). Caco-
2, AsPC-1, and Capan-2 cell suspensions (250 µL) were
placed in triplicate wells, the reactions started with the
addition of substrate, and cells were incubated at 37 °C for
120 min. At the desired time point, sample aliquots (35 µL)
were removed and added to 150 µL of acetonitrile (ACN)
containing 0.1% TFA. The mixtures were ﬁltered with a 0.45
µm ﬁlter at 1000g for 10 min at 4 °C. The ﬁltrate was then
analyzed Via reverse-phase HPLC.
(b) Stability in Human Plasma. The stability of the
prodrugs in human plasma was determined using the
procedure below. Undiluted plasma (250 µL) was added to
each well in triplicate, and substrate was added to initiate
the reactions that were conducted at 37 °C for 2 h. At various
time points, aliquots (35 µL) were removed and added to
150 µL of ACN containing 0.1% TFA. The mixtures were
ﬁltered with a 0.45 µm ﬁlter at 1000g for 10 min at 4 °C.
The ﬁltrate was then analyzed Via reverse-phase HPLC.
(c) Chemical Stability. The nonenzymatic hydrolysis of
the prodrugs was determined as described above, except that
each well contained pH 7.4 phosphate buffer (10 mmol/L)
instead of cell homogenate or human plasma.
(d) Resistance to Metabolism of Floxuridine and Its
Prodrugs by Thymidine Phosphorylase. The stability of
ﬂoxuridine and its prodrugs in the presence of thymidine
phosphorylase (TP) was assessed by incubating the desired
substrates (200 µM) with TP (2.0 ng/µL) in phosphate buffer
(pH 7.0) at 37 °C. Aliquots of the incubation mixture were
sampled at 0, 1, 3, 5, 10, 30, 60, and 120 min, and quenched
with cold acetonitrile (ACN) with 0.1% TFA, ﬁltered through
a 0.45 µm membrane, and analyzed for the concentrations
of prodrug, ﬂoxuridine, and 5-FU by HPLC.
[
3H]Gly-Sar Uptake Inhibition. Caco-2 cells at nine days
postseeding, and AsPC-1 and Capan-2 cells, both at four days
postseeding, were incubated with 10 µmol/L Gly-Sar (9.98
µmol/L Gly-Sar and 0.02 µmol/L [
3H]Gly-Sar) along with
various prodrug concentrations (5-0.05 mmol/L) for 30 min.
The cells were washed three times with ice-cold PBS and
solubilized with 10 mL of scintillation cocktail (ScintiVerse,
Fisher Scientiﬁc, St.Louis, MO), and the amount of cell-
associated radioactivity was determined by scintillation
counting (Beckman LS-9000, Beckman Instruments, Ful-
lerton, CA). IC50 values were determined using nonlinear
data ﬁtting (GraphPad Prism version 3.0).
Transport Studies. Caco-2 cell monolayers were grown
on collagen-coated polytetraﬂuoroethylene membranes for
21 to 24 days, and Capan-2 cell monolayers were grown on
the same type of membrane for 14 days. Transepithelial
electrical resistance (TEER) was monitored, and values of
240-280 Ω/cm
2 in Caco-2 and 380-420 Ω/cm
2 in Capan-2
(total area for both cells was 4.67 cm
2) were used in the
study. Apical side and basolateral sides of transwell inserts
were washed with MES (pH 6.0) and HEPES (pH 7.4),
respectively. Fresh MES and HEPES buffers were reapplied
to transwell inserts and incubated at 37 °C for 15 min.
Freshly prepared 0.1 mM drug solution in MES buffer (total
1.5 mL) was placed in the donor chamber, and the receiver
chamber was ﬁlled with HEPES buffer (total 2.5 mL)
Sampling from the receiver chamber (200 µL) was conducted
up to a period of2ha ttime intervals of 15, 30, 45, 60, 75,
90, and 120 min, at 37 °C and replaced with an equal volume
of fresh HEPES buffer to maintain sink conditions in the
receiver chamber. All samples were immediately acidiﬁed
with 0.1% TFA and analyzed by reverse-phase HPLC.
Data Analysis. The initial rates of hydrolysis were used
to obtain the apparent ﬁrst-order rate constants and to
calculate the half-lives. The apparent ﬁrst-order degradation
rate constants of various ﬂoxuridine prodrugs at 37 °C were
determined by plotting the logarithm of prodrug remaining
as a function of time. The slopes of these plots are related
to the rate constant k and given by
k)2.303× slope (log C vs time) (1)
The degradation half-lives were then calculated by the
equation
t1⁄2)0.693⁄k (2)
Statistical signiﬁcance was evaluated with GraphPad Prism
v. 3.0 by performing one-way analysis of variance with
posthoc Tukey’s test to compare means.
The apparent permeability (Papp) for the prodrugs was
calculated using the following equations:
Flux)Jss)dM⁄dt (3)
where Jss is the steady state ﬂux, M is the cumulative amount
of prodrug, and regenerated mono amino acid prodrug, drug
and 5-FU in the receiver compartment. The apparent perme-
ability was calculated from steady state ﬂux as follows:
Papp)
Jss
A× C0
(4)
where A is the surface area of monolayer exposed to the
permeant and C0 is the concentration of the prodrug in the
donor solution. The concentrations of ﬂoxuridine and its
Dipeptide Monoester Prodrugs of Floxuridine articles
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analyzed using HPLC.
HPLC Analysis. The concentrations of prodrugs and their
metabolites were determined on a Waters HPLC system
(Waters, Inc., Milford, MA). The HPLC system consisted
of two Waters pumps (model 515), a Waters autosampler
(WISP model 712), and a Waters UV detector (996 photo-
diode array detector) controlled by Waters Millennium 32
software (version 3.0.1). Samples were resolved in a Waters
Xterra C18 reverse-phase column (5 µm, 4.6 × 250 mm)
equipped with a guard column. The mobile phase consisted
of 1% HFBA/water (solvent A) and 1% HFBA/acetonitrile
(solvent B) with the solvent B gradient changing from
0-56% at a rate of 2%/min during a 28 min run. Standard
curves generated for each prodrug, and their parent drugs
were utilized for quantitation of integrated area under peaks.
The detection wavelength was 254 nm, and spectra were
acquired in the 220-380 nm range.
Cell Proliferation Assays. Cell proliferation studies were
conducted with AsPC-1 and Capan-2 cell lines. The cells
were seeded onto 96-well plates at 125,000 cells per well
and allowed to attach/grow for 24 h before drug solutions
were added. The culture medium (RPMI-1640 + 10% fetal
bovine serum) was removed, and the cells were gently
washed once with sterile pH 6.0 uptake buffer. Floxuridine
and ﬂoxuridine prodrugs were 2-fold serially diluted in pH
6.0 uptake buffer from 4 to 0.25 mmol/L. Buffer alone was
used as 100% viability control. The wash buffer was
removed, and 25 µL of drug solution per well was added
and incubated at 37 °C for 2 h with AsPC-1 cells and 4 h
with Capan-2 cells in the cell incubator. After this time
period, the drug solutions were removed and the cells
were gently washed twice with sterile uptake buffer. Fresh
culture medium was then added to each well after washing,
and the cells were allowed to recover for 24 h before
evaluating cell viability Via 2,3-bis[2-methoxy-4-nitro-5-
sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT)
assays. A mixture (30 µL) containing XTT (1 mg/mL) in
sterile RPMI-1640 without phenol red and phenazine metho-
sulfate (N-methyl dibenzopyrazine methyl sulfate in sterile
PBS, 0.383 mg/mL) reagents was added to the cells and
incubated at 37 °C for 1 h, after which the absorbance at
450 nm was read. GI50 values were calculated using
GraphPad Prism version 3.0 by nonlinear data ﬁtting.
Results
Floxuridine Prodrug Synthesis. Dipeptide ﬂoxuridine
prodrugs were synthesized using a method similar to that
described earlier.
11,13 The total prodrug yield for each
dipeptide was >15%, and the purity for all prodrugs was
>90% as determined by HPLC, where the impurity was the
parent drug, ﬂoxuridine. All prodrug structures and their
identities were conﬁrmed by ESI-MS and NMR. The data
for prodrug purity and mass are shown in Table 1.
Stability Studies. The experiments concerning prodrug
stability were performed at 37 °C in pH 7.4 phosphate
buffer. The estimated half-lives (t1/2) obtained from linear
regression of pseudo-ﬁrst-order plots of prodrug concen-
tration vs time for ﬂoxuridine prodrugs in pH 7.4
phosphate buffers alone and in Caco-2, AsPC-1, and
Capan-2 cell homogenates are listed in Table 2. Prodrug
metabolites such as ﬂoxuridine and 5-FU were monitored
along with prodrug disappearance in this experiment.
However, mass balance was not achieved because 5-FU
was metabolized even further and those metabolites
beyond 5-FU were not quantiﬁed (Figure 1). 5′ -L-
Isoleucyl-ﬂoxuridine exhibited the highest stability in all
media tested. Dipeptide prodrugs with at least one
aromatic amino acid moiety were next-best with regard
to stability in enzyme-containing solutions such as plasma
and cell homogenates, and those with two aromatic amino
acids also exhibited chemical stability that was similar to
that of 5′ -L-isoleucyl-ﬂoxuridine. All prodrugs exhibited
3- to 30-fold shorter half-lives in cell homogenates than
in pH 7.4 phosphate buffer suggesting enzyme-catalyzed
hydrolysis. With a few exceptions, the half-lives of all
monoester and dipeptide prodrugs tested exhibited similar
trends in the three cell homogenates and showed good
linear correlations (r
2 ) 0.87-0.93). The composition of
the amino acids in the dipeptide moiety exerted a profound
effect on the stability of the ester bond regardless of the
mode of attachment. Thus, glycyl-containing dipeptide
prodrugs were less stable in buffer alone compared to
dipeptide prodrugs containing one or two aromatic amino
acids. Glycyl-containing dipeptide prodrugs were also less
stable than the 5′ -L-glycyl ester prodrug. A comparison
of the stability of 5′ -L-isoleucyl-ﬂoxuridine in various
media with 5′ -L-isoleucyl-L-glycyl-ﬂoxuridine dramatically
illustrates this effect (Table 2).
Table 1. Analytical Data for Amino Acid Ester Prodrugs of Floxuridine
ESI-MS (M + H)
+
prodrug
% purity
(HPLC) required obsd
MW
(TFA salt) CLogP
a
5′ -L-valyl-L-phenylalanyl-ﬂoxuridine 95.3 493.2 494.1 606.4 0.04
5′ -L-leucyl-L-glycyl-ﬂoxuridine 93.2 417.2 417.1 544.4 -0.80
5′ -L-glycyl-L-leucyl-ﬂoxuridine 96.0 417.2 417.1 544.4 -0.80
5′ -L-phenylalanyl-L-tyrosyl-ﬂoxuridine 99.0 557.2 557.2 670.4 -0.14
5′ -L-phenylalanyl-L-glycyl-ﬂoxuridine 98.1 451.2 451.1 578.4 -1.20
5′ -L-isoleucyl-L-glycyl-ﬂoxuridine 92.7 417.2 416.9 544.4 -0.89
a Calculated using BioLoom.
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dine and Prodrugs. The metabolic stability of ﬂoxuridine
and its amino ester prodrugs was assessed using thymidine
phosphorylase. The results shown in Table 3 indicate that
ﬂoxuridine was rapidly degraded to the less active metabolite,
5-ﬂuorouracil, by thymidine phosphorylase. The amino acid
ester prodrugs of ﬂoxuridine were found to be quite resistant
to degradation by thymidine phosphorylase. Prodrugs con-
taining the glycyl moiety, 5′ -L-glycyl, 5′ -L-leucyl-L-glycyl,
5′ -L-glycyl-L-leucyl, 5′ -L-phenylalanyl-L-glycyl, and 5′ -L-
isoleucyl-L-glycyl ﬂoxuridine were 20- to 40-fold more stable
than ﬂoxuridine to degradation by thymidine phosphorylase.
The half-lives of 5′ -L-phenylalanyl-ﬂoxuridine, 5′ -L-isole-
ucyl-ﬂoxuridine, 5′ -L-valyl-L-phenylalanyl-ﬂoxuridine, and
5′ -L-phenylalanyl-L-tyrosyl-ﬂoxuridine were in excess of 500
min reﬂecting their superior resistance to metabolic degrada-
tion by thymidine phosphorylase. The results are consistent
with the stability of the prodrugs in buffer systems.
Table 2. Stability of Floxuridine Prodrugs in pH 7.4 Buffer and Biological Media
a
t1/2 (min)
cell homogenates
prodrug buffer pH 7.4 human plasma Caco-2 AsPC-1 Capan-2
5′ -L-valyl-ﬂoxuridine 304.0 ( 33.3 131.5 ( 54.1 9.4 ( 0.5 18.7 ( 6.7 5.2 ( 2.4
5′ -L-phenylalanyl-ﬂoxuridine 187.0 ( 19.0 62.8 ( 0.8 11.1 ( 9.9 11.8 ( 1.7 3.0 ( 0.1
5′ -L-leucyl-ﬂoxuridine 83.2 ( 1.7 82.4 ( 8.7 3.2 ( 0.2 2.0 ( 0.1 4.7 ( 2.1
5′ -L-isoleucyl-ﬂoxuridine 1194.5 ( 660.6 271.4 ( 3.2 192.3 ( 31.8 198.0 ( 70.2 139.9 ( 15.3
5′ -L-glycyl-ﬂoxuridine 85.5 ( 3.2 72.1 ( 15.0 24.1 ( 2.0 27.6 ( 5.8 49.7 ( 5.6
5′ -L-valyl-L-phenylalanyl-ﬂoxuridine 104.7 ( 7.0 76.0 ( 14.1 57.6 ( 9.3 51.6 ( 4.2 56.2 ( 12.8
5′ -L-leucyl-L-glycyl-ﬂoxuridine 23.2 ( 4.1 6.7 ( 0.3 4.1 ( 0.1 3.6 ( 0.8 3.9 ( 1.1
5′ -L-glycyl-L-leucyl-ﬂoxuridine 35.7 ( 0.9 24.6 ( 0.3 25.4 ( 2.7 13.0 ( 1.4 29.2 ( 0.7
5′ -L-phenylalanyl-L-tyrosyl-ﬂoxuridine 233.9 ( 6.6 80.6 ( 3.7 103.8 ( 55.5 59.7 ( 1.4 42.8 ( 0.0
5′ -L-phenylalanyl-L-glycyl-ﬂoxuridine 132.1 ( 10.2 9.7 ( 0.8 6.3 ( 0.6 10.2 ( 0.3 4.3 ( 0.9
5′ -L-isoleucyl-L-glycyl-ﬂoxuridine 33.5 ( 2.4 9.5 ( 0.5 20.5 ( 1.1 25.1 ( 5.8 18.7 ( 1.4
a Mean ( SD, n ) 3.
Figure 1. The metabolic pathway of ﬂoxuridine and ﬂoxuridine prodrugs with enzymes.
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dipeptide monoester prodrugs of ﬂoxuridine for PEPT1
determined using inhibition of Gly-Sar uptake in Caco-2,
AsPC-1, and Capan-2 cells are summarized in Table 4. All
ester prodrugs of ﬂoxuridine exhibited greater afﬁnity for
PEPT1 than the parent drug. Floxuridine showed minimal
inhibition of Gly-Sar uptake, and IC50 values were 8.43 (
2.66 mM, 6.63 ( 1.52 mM, and 16.06 ( 6.71 mM in Caco-
2, AsPC-1, and Capan-2 cells, respectively. 5′ -L-Isoleucyl-
L-glycyl-ﬂoxuridine displayed the highest afﬁnity for oli-
gopeptide transporters in Caco-2 cells (IC50 ) 0.39 ( 0.01
mM) and in AsPC-1 cells (IC50 ) 0.29 ( 0.00 mM) and
was second-best in Capan-2 cells (IC50 ) 0.44 ( 0.02 mM).
With the exception of 5′ -L-leucyl and 5′ -L-glycyl dipeptide
analogs with Caco-2 cells, all dipeptide prodrugs of ﬂoxu-
ridine exhibited 2- to 14-fold higher afﬁnity for oligopeptide
transporters than the corresponding 5′ -L-monoester prodrug.
In particular, dipeptide prodrugs with at least one aromatic
amino acid component consistently exhibited 3- to 5-fold
higher afﬁnity for the oligopeptide transporters than the
corresponding monoester prodrug in all three cell lines tested.
Caco-2 and Capan-2 Cell Permeability of Prodrugs
and Floxuridine. The apical-to-basolateral permeability of
mono amino acid/dipeptide monoester prodrugs of ﬂoxuri-
dine and parent ﬂoxuridine were determined at 37 °Ci n
Caco-2 and Capan-2 cell monolayers. Table 5 shows the
permeability values in the two cell systems. All ester
prodrugs of ﬂoxuridine exhibited 4- to 20-fold higher
permeability than ﬂoxuridine in Caco-2 cells. With the
exception of 5′ -L-valyl-L-phenylalanyl-ﬂoxuridine, the per-
meability of all other dipeptide prodrugs of ﬂoxuridine across
Caco-2 monolayers was 2- to 4-fold higher than the corre-
sponding 5′ -L-mono amino acid ester ﬂoxuridine prodrug.
The permeability trends in Caco-2 monolayers are consistent
with the afﬁnity data observed in uptake inhibition studies;
however, no simple correlations between permeability and
afﬁnity were evident. Floxuridine was impermeant with
Capan-2 cell monolayers; neither ﬂoxuridine nor its metabo-
lite 5-FU could be detected suggesting the possibility of
upregulation of metabolic enzymes such as TP and dihy-
dropyrimidine dehydrogenase (DPD) in Capan-2 cells. DPD
is the rate-limiting enzyme involved in the catabolism of
pyrimidines and is also the main enzyme involved in the
degradation of structurally related compounds like 5-FU
(Figure 1). Floxuridine permeability was indeed observed
in the presence of DPD inhibitors, dipyridamole and cisplatin;
however, it was 1,000- or 10,000-fold lower than that
obtained with Caco-2 cells (data not shown). The perme-
ability of 5′ -L-valyl-L-phenylalanyl-ﬂoxuridine across Caco-2
monolayers was quite low. 5′ -L-Phenylalanyl-L-tyrosyl-
ﬂoxuridine, however, exhibited dramatically lower perme-
ability in Capan-2 cells compared to its permeability in
Caco-2 cells. With the exception of 5′ -L-phenylalanyl-L-
tyrosyl-ﬂoxuridine, the permeability of the ﬂoxuridine ester
prodrugs in Caco-2 cells was about 2-fold higher than the
corresponding value in Capan-2 cells (r
2 ) 0.83). Unlike
Caco-2 monolayers, general permeability enhancement ef-
fects with dipeptide prodrugs compared to the corresponding
5′ -L-mono amino ester prodrug were not apparent with
Capan-2 cell monolayers.
Cell Proliferation Assays. GI50 values for ﬂoxuridine and
its 5′ -mono amino acid/dipeptide monoester prodrugs de-
termined in cell proliferation studies with the pancreatic
cancer cell lines, AsPC-1 and Capan-2, are shown in Table
6. All prodrugs exhibit 4- to 8-fold enhanced antiproliferative
activity in the two cell lines compared to parent ﬂoxuridine.
Thus, the GI50 values of all ﬂoxuridine prodrugs were in the
range of 1.65-3.36 mM in AsPC-1 and Capan-2 cells as
opposed to GI50 values of 22.85 mM and 17.63 mM for
ﬂoxuridine in AsPC-1 and Capan-2 cells, respectively. These
results are consistent with trends observed in Gly-Sar uptake
inhibition studies. Gly-Sar and Gly-Pro did not inhibit the
growth rate of Capan-2 cells. Additionally, 5′ -D-valyl-
ﬂoxuridine exhibited antiproliferative activity similar to that
of ﬂoxuridine and Gly-Sar, despite an afﬁnity for PEPT1
that was similar to that of other mono amino acid/dipeptide
monoester prodrugs of ﬂoxuridine.
Discussion
Amino acid ester prodrugs have been widely employed
to improve intestinal absorption of poorly permeant drugs.
The antivirals valacyclovir and valganciclovir
8,38 are early
examples of the clinical and commercial success of amino
acid ester prodrug strategies. The enhanced oral bioavail-
ability of these prodrugs
24,39 has been attributed to their
enhanced transport by intestinal oligopeptide transporters,
1,15,40
and to their efﬁcient bioconversion to the parent drug by
(38) Anand, B. S.; Dey, S.; Mitra, A. K. Current prodrug strategies
via membrane transporters/receptors. Expert Opin. Biol. Ther.
2002, 2 (6), 607–20.
(39) Steingrimsdottir, H.; Gruber, A.; Palm, C.; Grimfors, G.; Kalin,
M.; Eksborg, S. Bioavailability of aciclovir after oral administra-
tion of aciclovir and its prodrug valaciclovir to patients with
leukopenia after chemotherapy. Antimicrob. Agents Chemother.
2000, 44 (1), 207–9.
(40) Ganapathy, M. E.; Huang, W.; Wang, H.; Ganapathy, V.; Leibach,
F. H. Valacyclovir: a substrate for the intestinal and renal peptide
transporters PEPT1 and PEPT2. Biochem. Biophys. Res. Commun.
1998, 246 (2), 470–5.
Table 3. Stability of Floxuridine and Floxuridine Prodrugs
in the Presence of Thymidine Phosphorylase
a
prodrug/drug t1/2 (min)
ﬂoxuridine 6 ( 3
5′ -L-phenylalanyl-ﬂoxuridine >500
5′ -L-isoleucyl-ﬂoxuridine >500
5′ -L-glycyl-ﬂoxuridine 250 ( 54
5′ -L-valyl-L-phenylalanyl-ﬂoxuridine >500
5′ -L-leucyl-L-glycyl-ﬂoxuridine 138 ( 11
5′ -L-glycyl-L-leucyl-ﬂoxuridine 142 ( 10
5′ -L-phenylalanyl-L-tyrosyl-ﬂoxuridine >500
5′ -L-phenylalanyl-L-glycyl-ﬂoxuridine 119 ( 30
5′ -L-isoleucyl-L-glycyl-ﬂoxuridine 223 ( 54
a Mean ( SD, n ) 3.
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26,27 A variety of dipeptide and tripeptide
compounds and prodrugs have also been investigated for their
suitabilityassubstratesforthePEPT1transporter.
4,6,17,18,22,35,41-43
We had previously reported the synthesis and evaluation of
mono amino acid ester prodrugs of antiviral and anticancer
drugs such as ﬂoxuridine,
11,13,14 gemcitabine,
2 acyclovir,
15
and 2-bromo-5,6-dichloro-1-( -D-ribofuranosyl)benzimida-
zole (BDCRB).
2,44 These studies revealed that mono amino
acid ester prodrugs in general provide enhanced PEPT1-
mediated transport, a range of bioactivation rates, and
enhanced glycosidic bond resistance to metabolic enzymes
such as thymidine phosphorylase and cytidine deaminase.
In this report, we describe the synthesis of dipeptide
monoester prodrugs of ﬂoxuridine and their chemical stabil-
ity, bioactivation and transport in Caco-2 cells, a surrogate
for intestinal transport, and in two pancreatic duct cell lines,
AsPC-1 and Capan-2, that overexpress the PEPT1 trans-
porter. We also conducted similar studies with the mono
amino acid analogues for comparison.
(41) Eriksson, A. H.; Elm, P. L.; Begtrup, M.; Nielsen, R.; Steffansen,
B.; Brodin, B. hPEPT1 afﬁnity and translocation of selected Gln-
Sar and Glu-Sar dipeptide derivatives. Mol. Pharmaceutics 2005,
2 (3), 242–9.
(42) Li, J.; Tamura, K.; Lee, C. P.; Smith, P. L.; Borchardt, R. T.;
Hidalgo, I. J. Structure-afﬁnity relationships of Val-Val and Val-
Val-Val stereoisomers with the apical oligopeptide transporter in
human intestinal Caco-2 cells. J. Drug Targeting 1998, 5 (5), 317–
27.
(43) Tamura, K.; Bhatnagar, P. K.; Takata, J. S.; Lee, C. P.; Smith,
P. L.; Borchardt, R. T. Metabolism, uptake, and transepithelial
transport of the diastereomers of Val-Val in the human intestinal
cell line, Caco-2. Pharm. Res. 1996, 13 (8), 1213–8.
(44) Lorenzi, P. L.; Landowski, C. P.; Song, X.; Borysko, K. Z.;
Breitenbach, J. M.; Kim, J. S.; Hilﬁnger, J. M.; Townsend, L. B.;
Drach, J. C.; Amidon, G. L. Amino acid ester prodrugs of
2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole en-
hance metabolic stability in vitro and in vivo. J. Pharmacol. Exp.
Ther. 2005, 314 (2), 883–90.
Table 4. [
3H]Gly-Sar Uptake Inhibition of Floxuridine and Floxuridine Prodrugs in Caco-2, AsPC-1, and Capan-2 Cells
a
IC50
prodrug/drug Caco-2 (mM) AsPC-1 (mM) Capan-2 (mM)
ﬂoxuridine 8.43 ( 2.66 6.63 ( 1.52 16.06 ( 6.71
5′ -L-valyl-ﬂoxuridine 1.88 ( 0.18 2.91 ( 0.38 2.41 ( 0.28
5′ -L-phenylalanyl-ﬂoxuridine 1.99 ( 0.82 1.97 ( 0.09 3.71 ( 2.13
5′ -L-leucyl-ﬂoxuridine 3.51 ( 0.11 2.60 ( 0.16 1.45 ( 0.07
5′ -L-isoleucyl-ﬂoxuridine 0.72 ( 0.03 4.12 ( 1.75 2.38 ( 0.12
5′ -L-glycyl-ﬂoxuridine 2.28 ( 0.59 2.71 ( 0.53 2.79 ( 0.08
5′ -L-valyl-L-phenylalanyl-ﬂoxuridine 2.88 ( 0.01 1.03 ( 0.08 0.46 ( 0.02
5′ -L-leucyl-L-glycyl-ﬂoxuridine 3.80 ( 0.60 0.51 ( 0.03 0.34 ( 0.01
5′ -L-glycyl-L-leucyl-ﬂoxuridine 5.49 ( 1.48 1.89 ( 0.11 1.67 ( 0.05
5′ -L-phenylalanyl-L-tyrosyl-ﬂoxuridine 0.66 ( 0.25 0.61 ( 0.18 1.20 ( 0.16
5′ -L-phenylalanyl-L-glycyl-ﬂoxuridine 0.78 ( 0.56 0.88 ( 0.22 0.79 ( 0.02
5′ -L-isoleucyl-L-glycyl-ﬂoxuridine 0.39 ( 0.01 0.29 ( 0.00 0.44 ( 0.02
a Mean ( SD, n ) 3.
Table 5. Apparent Permeability Coefﬁcients (Papp)o f
Floxuridine and Its Amino Acid Ester Prodrugs in the
Apical-to-Basolateral Direction Across Caco-2 and Capan-2
Monolayers
a
Papp (×10
6 cm/s)
prodrug/drug Caco-2 Capan-2
ﬂoxuridine 0.69 ( 0.10 0.00 ( 0.00
5′ -L-phenylalanyl-ﬂoxuridine 4.09 ( 0.52 2.20 ( 1.33
5′ -L-glycyl-ﬂoxuridine 3.76 ( 0.46 1.67 ( 0.42
5′ -L-isoleucyl-ﬂoxuridine 2.56 ( 0.13 0.76 ( 0.10
5′ -L-valyl-L-phenylalanyl-ﬂoxuridine 0.83 ( 0.09 1.16 ( 0.42
5′ -L-leucyl-L-glycyl-ﬂoxuridine 3.79 ( 0.56 1.50 ( 0.15
5′ -L-glycyl-L-leucyl-ﬂoxuridine 6.29 ( 2.18 1.42 ( 0.08
5′ -L-phenylalanyl-L-tyrosyl-ﬂoxuridine 7.50 ( 0.78 0.24 ( 0.10
5′ -L-phenylalanyl-L-glycyl-ﬂoxuridine 12.60 ( 1.61 6.46 ( 2.09
5′ -L-isoleucyl-L-glycyl-ﬂoxuridine 11.40 ( 1.10 4.09 ( 2.90
a Mean ( SD, n ) 3.
Table 6. Cell Growth Inhibition in AsPC-1 and Capan-2
Cells
a
GI50 (mM)
prodrug AsPC-1 Capan-2
ﬂoxuridine 22.9 ( 5.7 17.6 ( 2.2
Mono Amino Acid Prodrugs
5′ -L-phenylalanyl-ﬂoxuridine 1.8 ( 0.1 2.4 ( 0.2
5′ -L-glycyl-ﬂoxuridine 2.6 ( 0.5 3.4 ( 0.3
5′ -L-isoleucyl-ﬂoxuridine 3.9 ( 0.8 2.8 ( 0.4
5′ -L-leucyl-ﬂoxuridine 2.9 ( 0.4 6.8 ( 4.1
5′ -L-valyl-ﬂoxuridine 3.9 ( 0.1 3.0 ( 0.1
Dipeptide Prodrugs
5′ -L-valyl-L-phenylalanyl-ﬂoxuridine 1.8 ( 0.5 1.8 ( 0.2
5′ -L-leucyl-L-glycyl-ﬂoxuridine 1.7 ( 0.1 3.0 ( 0.3
5′ -L-glycyl-L-leucyl-ﬂoxuridine 1.8 ( 0.3 2.0 ( 0.3
5′ -L-phenylalanyl-L-tyrosyl-ﬂoxuridine 4.0 ( 0.7 2.2 ( 0.3
5′ -L-phenylalanyl-L-glycyl-ﬂoxuridine 2.8 ( 0.3 2.6 ( 0.5
5′ -L-isoleucyl-L-glycyl-ﬂoxuridine 7.0 ( 3.1 2.4 ( 0.4
Controls
5′ -D-valyl-ﬂoxuridine nd
b 19.6 ( 2.9
glycylsarcosine (Gly-Sar) nd 25.7 ( 8.1
glycylproline (Gly-Pro) nd 29.5 ( 6.5
a Mean ( SD, n ) 3.
b Not determined.
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7.4 buffers than the corresponding mono amino acid ester
prodrugs. Since no mono amino ester prodrug degradation
products were detected, it is quite likely that the dipeptide
monoester prodrugs degrade Via parallel pathways similar
to those suggested for Gly-Phe dipeptide alkyl ester prodrugs
by Larsen and colleagues.
45 Thus, in addition to hydrolysis
of the ester bond producing the dipeptide, a diketopiperazine
cyclization product is also possible due to intramolecular
condensation of the ester group with the free amino group
of the dipeptide monoester prodrug. It has been reported that
the rate of intramolecular aminolysis is comparable to that
of ester hydrolysis and that cyclization is negligible at pH
values below 6.
45-47 Indeed, the formation of diketopiper-
izine was observed in a chemical stability study at pH 10
but not at lower pH values (data not shown). The stability
of the prodrugs in buffer was clearly inﬂuenced by the
prodrug moiety of amino acids; dipeptide prodrugs containing
glycyl and leucyl moieties were less stable than those
containing phenylalanyl dipeptide prodrugs.
Dipeptide prodrugs with two aromatic residues were the
most stable in buffer as well as in cell homogenates. The
enzymatic stabilities of 5′ -L-phenylalanyl-L-tyrosyl-ﬂoxuri-
dine and 5′ -L-valyl-L-phenylalanyl-ﬂoxuridine were signiﬁ-
cantly enhanced compared to the other prodrugs, suggesting
that bulky amino acids such as tyrosine and phenylalanine
protect against enzyme-catalyzed hydrolysis of the ester
linkage. The stability proﬁles of 5′ -L-phenylalanyl-L-tyrosyl-
ﬂoxuridine and 5′ -L-valyl-L-phenylalanyl-ﬂoxuridine in cell
homogenates, particularly Caco-2, suggest that activation to
the parent drug following transport would be much slower
than monoester prodrugs such as 5′ -L-valyl-ﬂoxuridine and
reference prodrugs such as valacyclovir. The improved
stability in biological surrogate media would facilitate
prolonged systemic circulation of intact prodrugs for en-
hanced therapeutic action.
The results of the afﬁnity studies of the mono amino acid
ester prodrugs for the oligopeptide transporter in Caco-2 cells
were generally consistent with previous ﬁndings in our
laboratory,
14 as well as with amino acid prodrugs of acyclovir
reported by Beuchamp and colleagues.
48 No signiﬁcant trends
were noticeable regarding the afﬁnity of the mono amino
acid ester prodrugs in AsPC-1 and Capan-2 cells. With the
exception of leucyl ﬂoxuridine, the afﬁnities of the mono
amino ester prodrugs were lower in AsPC-1 and Capan-2
compared to those observed with Caco-2 cells. Dipeptide
monoester prodrugs exhibited enhanced afﬁnity in all cell
lines depending on the nature of the N-terminal amino acid
moiety. Thus, attachment of isoleucyl, phenylalanyl, or leucyl
groups to glycyl ﬂoxuridine yielded 3- to 9-fold enhancement
in afﬁnity for the transporter. However, attachment of a
glycyl promoiety to the N-terminus of leucyl ﬂoxuridine did
not result in afﬁnity enhancement. These ﬁndings are
consistent with previous observations on the importance of
the amino acid composition at the N-terminus in improving
afﬁnity for the PEPT1 oligopeptide transporter.
22
The results of apparent permeability of the ﬂoxuridine
prodrugs across Caco-2 monolayers are consistent with the
afﬁnity trends observed in Gly-Sar uptake inhibition studies.
In light of previous studies with mono amino acid prodrugs
of ﬂoxuridine that revealed excellent linear correlations
between Caco-2 permeability and PEPT1-mediated transport
in HeLa/PEPT1 cells,
13 the enhanced permeability of the
dipeptide monoester prodrugs across Caco-2 monolayers may
indicate enhanced PEPT1-mediated transport of the dipeptide
prodrugs. The extremely low permeability of 5′ -L-valyl-L-
phenylalanyl-ﬂoxuridine in Caco-2 and Capan-2 cells and
that of 5′ -L-phenylalanyl-L-tyrosyl-ﬂoxuridine in Capan-2
cells are not consistent with permeability proﬁles of 5′ -L-
valyl-ﬂoxuridine in Caco-2 cells reported earlier
13 or of 5′ -
L-phenylalanyl-ﬂoxuridine in this study. The low permeabil-
ity of these prodrugs is similar to the low permeability across
Caco-2 monolayers observed for monoester prodrugs con-
taining L-valyl-L-tyrosyl dipeptide promoieties.
17 The esti-
mated CLogP values (Table 1) of these two were indicative
of their being the most lipophilic prodrugs examined, and
the contribution of MDR and MRP efﬂux transporters in
permeability studies, therefore, was tested. However, the
permeability of 5′ -L-phenylalanyl-L-tyrosyl-ﬂoxuridine in
Capan-2 cells was not affected by 1 mM verapamil, a known
efﬂux pump inhibitor (data not shown).
The permeabilities of the ﬂoxuridine prodrugs were
consistently lower in Capan-2 cells compared to their
corresponding values in Caco-2 monolayers. Dipeptide
monoester prodrugs did not exhibit any signiﬁcant enhance-
ment in permeability compared to the mono amino acid ester
prodrugs in Capan-2 cells. Although the permeability across
Capan-2 cells for all prodrugs was signiﬁcantly higher than
that of ﬂoxuridine alone, meaningful trends based on
structure-activity correlations between transporter afﬁnity
and membrane permeability are not evident with the limited
set of promoieties examined in this study.
The detection of only 5-FU in the basolateral receiver
compartment following transport of ﬂoxuridine across Caco-2
monolayers suggests the instability of the glycosidic bond
of ﬂoxuridine. The extent of conversion of prodrugs to 5-FU
following transport was substantially lower in Caco-2 and
Capan-2 cells. The average percent 5-FU observed in the
basolateral compartment in Caco-2 monolayer studies (43%;
range 0-92%) was higher than the corresponding average
with Capan-2 monolayers (15%; range 0-35%). In general,
conversion of dipeptide prodrugs to 5-FU following transport
(45) Larsen, S. W.; Ankersen, M.; Larsen, C. Kinetics of degradation
and oil solubility of ester prodrugs of a model dipeptide (Gly-
Phe). Eur. J. Pharm. Sci. 2004, 22 (5), 399–408.
(46) Goolcharran, C.; Borchardt, R. T. Kinetics of diketopiperazine
formation using model peptides. J. Pharm. Sci. 1998, 87 (3), 283–
8.
(47) Jensen, E.; Bundgaard, H. Peptide esters as water-soluble prodrugs
for hydroxyl containing agents: Chemical stability and enzymatic
hydrolysis of benzyl esters of glycine, diglycine and triglycine.
Int. J. Pharm. 1991, 71, 117–125.
(48) Beauchamp, L. M.; Orr, G. F.; de Miranda, P.; Burnette, T.;
Kernitsy, T. A. Amino acid ester prodrugs of acyclovir. AntiViral
Chem. Chemother. 1992, 3, 157–164.
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observed with mono amino ester prodrugs. The results are
consistent with stability proﬁles of ﬂoxuridine and its
prodrugs in the presence of thymidine phosphorylase, an
enzyme involved in the in ViVo for phosphorytic cleavage
of ﬂoxuridine.
49 Floxuridine was rapidly cleaved by thymi-
dine phosphorylase, while all amino acid ester prodrugs
examined in this study were at least 20-fold more stable to
glycosidic bond cleavage by thymidine phosphorylase (Table
3). The role of esteriﬁcation of the hydroxyl groups in
protecting glycosidic bond cleavage by thymidine phospho-
rylase, the rate-determining step in deprotection and in
metabolic conversion of ﬂoxuridine to 5-FU, has been
discussed in a previous study.
13
The cell proliferation studies in the pancreatic duct cancer
cell lines conﬁrmed the enhanced potency of the amino acid
ester prodrugs compared to parent ﬂoxuridine. In many cases,
dipeptide prodrugs exhibited better GI50 values even though
the GI50 values for dipeptide monoester prodrugs in the two
cell lines were not signiﬁcantly different from those obtained
with mono amino acid ester prodrugs. The GI50 values of
prodrugs did not exhibit any discernible correlations with
their permeability and/or bioactivation proﬁles in these cells.
The lack of potency enhancement of 5′ -D-valyl-ﬂoxuridine
in Capan-2 cells compared to ﬂoxuridine suggests that
activation of the prodrugs to the parent is essential for
cytotoxic action and is enzyme-speciﬁc. The different amino
acid promoieties of prodrugs may contribute to the different
rates of prodrug activation inside cancer cells by particular
activation enzymes. Therefore, it would be difﬁcult to discern
a meaningful correlation between GI50 values and prodrug
permeabilities with a limited experimental time course. This
characteristic could lead to enzyme targeted activation of
prodrugs at target sites after their membrane permeation.
Intracellular anabolism of ﬂoxuridine prodrugs may il-
lustrate that transported drugs are converted to ﬂoxuridine
and 5-FU via a sequential enzymatic pathway with higher
concentrations of TP present in tumor tissue (Figure 2).
14,49
Taken together, our results indicate that the dipeptide
monoester prodrugs exhibit signiﬁcantly higher afﬁnity for
the PEPT1 oligopeptide transporter and 2- to 4-fold higher
permeability in Caco-2 and Capan-2 cells than the corre-
sponding mono amino acid ester prodrugs, suggesting their
potential for improved oral absorption and uptake in cancer
cells. Therefore, dipeptide prodrugs might possess an ad-
vantage over amino acid monoester prodrugs for cancer target
delivery. Three dipeptide prodrugs of ﬂoxuridine, 5′ -L-
phenylalanyl-L-tyrosyl-ﬂoxuridine, 5′ -L-phenylalanyl-L-gly-
cyl-ﬂoxuridine and 5′ -L-isoleucyl-L-glycyl-ﬂoxuridine, dis-
played signiﬁcantly higher afﬁnity for the PEPT1 oligopeptide
transporter and Caco-2 permeability. The delayed enzymatic
activation, enhanced metabolic resistance and superior af-
ﬁnity to oligopeptide transporters of dipeptide prodrugs may
facilitate their prolonged systemic circulation and enhanced
therapeutic action. With its display of respectable stability
in biological surrogate media and its approximately 2- to
3-fold shorter half-life in cancer cell homogenates than ones
in human plasma and Caco-2 cell homogenates, 5′ -L-
phenylalanyl-L-tyrosyl-ﬂoxuridine could be an optimal can-
didate for cancer cell targeting with enzyme-speciﬁc activation.
Abbreviations Used
XTT, sodium 3′ -[1-(phenylaminocarbonyl)-3,4-tetrazo-
lium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate;
PMS, N-methyl dibenzopyrazine methyl sulfate.
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Figure 2. Intracellular anabolism of ﬂoxuridine prodrugs.
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